Oral anticoagulation does not modify mortality in people with heart failure in sinus rhythm, with rivaroxaban showing no difference in all-cause death compared to placebo (OR 0.99).
Systematic Review (n=5,498)
Estimación del efecto: OR 0.99 (95% CI 0.87 to 1.13)
Tasa de eventos absoluta: 22.5% vs 22.7%
People with chronic heart failure (HF) are at risk of thromboembolic events, including stroke, pulmonary embolism, and peripheral arterial embolism; coronary ischaemic events also contribute to the progression of HF. The use of long-term oral anticoagulation is established in certain populations, including people with HF and atrial fibrillation (AF), but there is wide variation in the indications and use of oral anticoagulation in the broader HF population.
Shantsila et al. (Tue,) conducted a systematic review in Heart failure in sinus rhythm (n=5,498). Oral anticoagulants (Rivaroxaban, Warfarin) vs. Placebo or no treatment was evaluated on All-cause death (Rivaroxaban vs Placebo) (OR 0.99, 95% CI 0.87 to 1.13). Oral anticoagulation does not modify mortality in people with heart failure in sinus rhythm, with rivaroxaban showing no difference in all-cause death compared to placebo (OR 0.99).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: